RxDoctor Payments Data

Amy Odom, NP

Gerontology · Mobile, ALNPI 1750863726

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $655, 9.4 times the $70 reported in 2021.

$1,219in general payments, 2019–2025

Across 58 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$191
  • Boehringer Ingelheim$166
  • GSK$148
  • AbbVie$133
  • Jazz Pharmaceuticals Inc.$127
  • Takeda Pharmaceuticals U.S.A., Inc.$118
  • plus $337 from 10 others

What the payments were for

  • Food & beverage$1,219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,219 in reported general payments places this provider in the 70th percentile of 143 gerontology providers in Alabama.

See all gerontology providers in Alabama

Medicare billing

Part B allowed, 2024
$61,578
Medicare patients
405
Services billed
845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$79,775
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$39,724
Spiriva RespimatTiotropium Bromide18$12,473
Breo ElliptaFluticasone/Vilanterol25$11,527
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,328
Albuterol Sulfate HfaAlbuterol Sulfate156$2,931
Wixela InhubFluticasone Propion/Salmeterol14$2,790
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,990
Azelastine Hcl44$1,436
Fluticasone Propionate62$893
Azithromycin31$724
Doxycycline Hyclate59$452
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$267
Prednisone149$240
Levocetirizine Dihydrochloride15$104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$148$99,630153 claims
AstraZenecaBreztri Aerosphere$191$39,72447 claims
Boehringer IngelheimSpiriva Respimat$166$12,47318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 143 gerontology providers in Alabama.

Other gerontology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →